Skip to main content

Table 1 Patient and tumor characteristics

From: Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes

  All patients (n = 30) Castrate-resistant (n = 11) Castrate-sensitive (n = 19)
Age, years
Median (range)
71 (56–83) 72 (56–83) 69 (57–80)
Pre-salvage PSA, ng/ml
Median (range)
3.63 (0.05–77) 3.16 (0.05–12.8) 4.1 (0.65–77)
Pre-salvage imaging, n (%)   
Ga68 PSMA PET 30 (100%) 11 (100%) 19 (100%)
mpMRI 11 (37%) 4 (36%) 7 (37%)
Location of local recurrence, n (%)   
Prostate-only 18 (60%) 8 (73%) 10 (53%)
Prostate and SV 10 (33%) 3 (27%) 7 (37%)
SV-only 2 (7%) 0 (0%) 2 (11%)
Staging at recurrence, n (%)   
T-stage ≥ T3 (locally advanced) 14 (47%) 6 (55%) 8 (42%)
Node positive (regional) 7 (23%) 3 (27%) 4 (21%)
Oligo-metastatic 1 (3%) 1 (9%) 0 (0%)
Histologic confirmation, n (%)   
Yes 18 (60%) 6 (55%) 12 (63%)
Median Gleason score1 (range) 9 (8–10)   
  1. Note that 83% of patients had high-risk features at recurrence (either castrate-resistant, Gleason ≥ 8, T-stage ≥ T3, or node positive)
  2. SBRT, stereotactic body radiation therapy; PSA, prostate specific antigen; mpMRI, multi-parametric magnetic resonance imaging; Ga68-PSMA, gallium-68 prostate specific membrane antigen positron; PET, positron emission tomography; SV, seminal vesicles
  3. 1Data was available for 8 patients